Nuro is an AI-enabled early pricing and market access platform. It predicts price potential, models likely health technology assessment (HTA) outcomes, identifies payer evidence gaps and flags early payer risk for pipeline and business development (BD) assets, bringing analogue data, HTA precedent and competitive intelligence together to produce rapid, defensible assessments when evidence is limited.

Nuro is for Early Market Access, Pricing and Health Economics and Outcomes Research (HEOR) teams shaping pricing, value and access strategy for pipeline and BD assets years before launch. It helps teams working with limited early-phase data and tight timelines estimate pricing potential, assess payer risk and build clear recommendations for forecasting, R&D and BD.

Nuro reads your asset’s target product profile (TPP), finds the closest approved analogues across markets in that indication, and derives a defensible price corridor – net and list – anchored to what payers actually accepted. It benchmarks realistic pricing and reimbursement potential, not a top-down guess.

Nuro models likely HTA outcomes for your asset by matching its profile to real HTA precedent and payer evidence across markets, surfacing the evidence gaps and considerations most likely to drive outcomes and impact access.

Nuro compares your asset’s evidence base against precedent and pinpoints the evidence gaps that drive payer pushback, so teams can see payer risk early and plan mitigations across scenarios.

Nuro spans 30+ markets, US and ex-US, with consistent pricing, HTA and payer intelligence across all of them.

Nuro is built on a regulatory and commercial data foundation covering every approved product since 1995, with 450+ data points per drug spanning pricing, HTA and evidence, with built-in analogue and competitor search.

Nuro provides consultancy-grade pricing and access assessments consistently, in minutes and repeatable across your whole portfolio, freeing expert time for the judgment calls that need it.